gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · TRDAHealthcarePharmaceuticals

Entrada Therapeutics, Inc. Common Stock (TRDA)

$5.06+7.20%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$4.72▼ 30.38% in range
Nov 3, 2025Low $4.37 · High $16.03Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Entrada Therapeutics closed at $5.06 on Nov 4, up 7.20%, 68.4% below its 52-week closing high. Volume of 497.7K shares was 1.19× its 20-day average (close to normal).

Split-adjusted performance: -6.6% over one month, -68.4% over six months, -25.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $898K, down 53.9% from a year earlier, with a net margin of -4762.0%.

Short interest was 3.3M shares at the Oct 15 settlement, up 9.4% from the prior report (13.0% of float, 8.6 days to cover).

Market cap$197.0M38.9M shares
Revenue · quarter$898.0K−53.9% YoY
Diluted EPS$-1.01—
P/E · TTM—P/S 42.0×
Net margin-4,762.0%Gross 100.0%
Dividend yieldNone
52-week range4.37 – 16.03−68.4% from high
Volume497.7K1.19× 20-day avg
Volatility · 60d86.2%Annualised
Short % of float13.0%8.6 days to cover
Net cash$223.0MCash $223.0M
Next earnings—Not scheduled
Split-adjusted performance
1W +4.5%1M −6.6%3M −26.3%6M −68.4%YTD −50.8%1Y −25.4%3Y −67.1%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum12
Revenue growth21
Net margin8
Value (low P/E)—
Size48

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short3.3M+9.4% vs prior
Days to cover8.6Settled Oct 15
% of float13.0%
Short vol. 10d43.2%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TRDAEntrada Therapeutics$5.06+7.20%−68.4%−53.9%−4762.0%—$197.0M
NAGENiagen Bioscience$2.52+6.78%−49.3%−4.3%3.2%12.5$199.4MCompare
AKBAAkebia Therapeutics$0.6947−4.28%−53.1%−21.4%−18.1%—$192.5MCompare
UPBUpstream Bio$3.70+9.14%−59.7%−17.5%−5136.1%—$202.7MCompare
RNACCartesian Therapeutics$6.82+6.40%−18.2%−100.0%——$206.3MCompare
ALXOALX Oncology Holdings$1.36+5.43%−34.9%———$188.1MCompare
BBOTBridgeBio Oncology Therapeutics$2.30−0.86%−72.4%———$184.4MCompare
KROSKeros Therapeutics$10.830.00%−8.1%−100.0%——$214.7MCompare
WHWKWhitehawk Therapeutics$3.17+2.26%−23.6%———$180.7MCompare

News about Entrada Therapeutics

All news →
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 StudyGlobeNewswire Inc. · Oct 14, 2026▲ PositiveEntrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45GlobeNewswire Inc. · Oct 14, 2026▲ PositiveEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · Sep 2, 2026NeutralIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 StudyGlobeNewswire Inc. · Jun 2, 2026▲ PositiveINVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLCGlobeNewswire Inc. · May 18, 2026▼ Negative

Quick answers

What does Entrada Therapeutics do?
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible.
What is TRDA's market cap?
$197.02M, based on the Nov 4 close of $5.06.
Does Entrada Therapeutics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TRDA is sold short?
3.3M shares, 13.0% of float, as of Oct 15, 2026.
What sector is TRDA in?
Healthcare, in the Pharmaceuticals industry.

About Entrada Therapeutics

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

HQ: Boston, MA152 employeesListed Oct 29, 2021entradatx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology